Continuous Versus Cyclic Use of Oral Contraceptive Pills in Adolescents
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The primary purpose of this study is to compare the compliance rates of adolescents who take oral contraceptives (OCPs) continuously to those who take OCPs cyclically.
| Condition | Intervention | Phase |
|---|---|---|
|
Contraception |
Drug: Desogestrel-Ethinyl Estradiol 21 tablets Drug: Desogestrel-Ethinyl Estradiol 28 tablets |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Prevention |
| Official Title: | Continuous Versus Cyclic Use of an Oral Contraceptive Pills in Adolescents |
- The primary objective is to compare the compliance rates of adolescents who take OCPs continuously to those who take OCPs cyclically. [ Time Frame: 1 year ] [ Designated as safety issue: No ]
- The number of girls who have positive pregnancy test results at 12 months [ Time Frame: 1 year ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 130 |
| Study Start Date: | May 2006 |
| Estimated Study Completion Date: | May 2009 |
| Estimated Primary Completion Date: | May 2008 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 |
Drug: Desogestrel-Ethinyl Estradiol 21 tablets
The participants in the continuous study arm will be given 4 packs of Marvelon-21, so that they can take the pills continuously for 84 days followed by no medication for 7 days. During these 7 days, the participant will have a withdrawal bleed. This sequence is repeated by the participant for a total of 12 months. Each patient in the continuous arm will have 4 withdrawal bleeds per year.
Other Name: Marvelon-21
|
| Active Comparator: 2 |
Drug: Desogestrel-Ethinyl Estradiol 28 tablets
The participants in the cyclical arm of the study will be given 3 packs of Marvelon-28 and asked to take all the pills in the packet, including the placebo pills. During the week of placebo pills, these participants will have a withdrawal bleed. Each patient in the cyclical arm will have 12 withdrawal bleeds per year. The duration of study drug treatment for both arms is 12 months.
Other Name: Marvelon-28
|
Detailed Description:
Oral contraceptive pills have traditionally been prescribed in a cyclical manner, where there are 21-24 days of active pills and 4-7 days of placebo pills or a pill-free interval, creating a 28-day cycle. It has now been proven that as long as a woman has both estrogen and progesterone, her uterine lining is protected and is thin. To that effect, a new OCP (Seasonale®, Barr Laboratories, Pomona, NY) has been packaged in the United States that combines 84 days of active pills with 7 days of placebo pills. This allows a withdrawal bleed every 3 months.
Like in adult women, OCPs are the most popular form of birth control and cycle control in adolescents. But, for a variety of reasons, adolescents tend to have poorer compliance when taking OCPs. Adult women tend to be noncompliant about 6% of the time, but, by the end of one year, adolescents have a non-compliance rate of 34-66%.
There have been few studies that even describe improved compliance and decreased ovarian follicular development in women who take OCPs continuously, which could be beneficial in decreasing the rate of adolescent pregnancy. The majority of the studies looking at continuous use of OCPs have been performed in adult women. At present, there has been only one article that has addressed the use of continuous OCPs in adolescents. Sucato and Gold discussed the indications of continuous use of OCPs, how to prescribe them, and what type of progestin to use; but they did not specifically examine compliance or the safety and efficacy of continuous OCPs in adolescents. We plan to evaluate these issues in our study.
Eligibility| Ages Eligible for Study: | 15 Years to 18 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Female
- Age 15 to 18
- Presenting to the Gynecology and Adolescent Medicine Clinic for contraception
Exclusion Criteria:
- Prior use of the study medication with no improvement in symptoms
- Any medical condition that indicates continuous OCPs (i.e. acute menorrhagia, dysmenorrhea that did not previously respond to cyclical OCP use)
- Personal history of or current thromboembolic disorder
- First-degree relative(s) with thromboembolic disorder
- Cerebrovascular disease
- Coronary artery disease
- Cardiac valvular disease
- Hypertension (systolic blood pressure > 160 mmHg or diastolic > 100 mmHG)
- Diabetes with retinopathy/neuromyopathy/nephropathy)
- Breast cancer
- Endometrial cancer
- Undiagnosed abnormal uterine bleeding
- Cholestatic jaundice of pregnancy
- Hepatic tumor
- Known or suspected pregnancy
- Less than 6 months postpartum if breastfeeding
- Classic migraine with aura or any other neurological signs
- Gallbladder disease
- Taking any medications known to affect the efficacy of OCPs (i.e. phenytoin, phenobarbital, primidone, carbamazepine, griseofulvin, rifampin)
Contacts and Locations| Contact: Lisa Allen, MD | 416-813-6188 | lisa.allen@sickkids.ca |
| Canada, Ontario | |
| The Hospital for Sick Children | Recruiting |
| Toronto, Ontario, Canada, M5G 1X8 | |
| Contact: Lisa Allen, MD 416 813 6188 lisa.allen@sickkids.ca | |
| Principal Investigator: Lisa Allen, MD | |
| Principal Investigator: Sari Kives, MD | |
| Sub-Investigator: Rachel Spitzer, MD | |
| Sub-Investigator: Karen Leslie, MD | |
| Principal Investigator: | Lisa Allen, MD | The Hospital for Sick Children, Toronto Canada |
More Information
No publications provided by The Hospital for Sick Children
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Lisa Allen/Principal Investigator, The Hospital for Sick Children |
| ClinicalTrials.gov Identifier: | NCT00326404 History of Changes |
| Other Study ID Numbers: | 1000008437 |
| Study First Received: | May 12, 2006 |
| Last Updated: | July 17, 2008 |
| Health Authority: | Canada: Health Canada |
Keywords provided by The Hospital for Sick Children:
|
Oral Contraceptives Adolescents Compliance |
Additional relevant MeSH terms:
|
Contraceptive Agents Estradiol valerate Estradiol 3-benzoate Estradiol 17 beta-cypionate Desogestrel Contraceptives, Oral Contraceptives, Oral, Combined Estradiol Polyestradiol phosphate Ethinyl Estradiol |
Reproductive Control Agents Physiological Effects of Drugs Pharmacologic Actions Therapeutic Uses Contraceptive Agents, Female Estrogens Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Progestins Contraceptives, Oral, Synthetic |
ClinicalTrials.gov processed this record on May 16, 2013